RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Bevacizumab for Advanced Lung Non-Squamous Non-Small Cell Carcinoma

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR.

Official registry: https://clinicaltrials.gov/study/NCT04181060 · National Cancer Institute (NCI) · enrollment listed as 300

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Bevacizumab, Biospecimen Collection, or Computed Tomography. The registry lists allocation as randomized. This phase III trial compares the effect of bevacizumab and osimertinib combination vs.

They plan to enroll about 300 people at 604 sites. Taking part typically means taking a study drug (or dummy pill), an infusion or injection of a biologic, a procedure as part of the study plus check-ins.

Official title (unrewritten)

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib

Primary outcome (registry wording): Progression-free survival (PFS)

Who it is for (from inclusion criteria)

Ages 18 Years to any
Patient must have a pathologically-confirmed diagnosis of non-squamous, non-small cell lung cancer (NSCLC)
Patient must not have received any prior treatment with an anti-VEGF agent
Patient must not have any risk factors for anti-VEGF administration, specifically, hemoptysis, active cardiovascular disease, uncontrolled hypertension, significant proteinuria (screening urinalysis \> 300 mg/dl) and tumor invading major blood vessels
Patient must not have had any prior systemic treatment for metastatic disease
Patient must be ≥ 18 years of age
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for side effects in nursing infants with the treatment regimens being used

Who the registry excludes

People the protocol lists as excluded — the study team must confirm.

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

604 listed

Anchorage Associates in Radiation Medicine — Anchorage, Alaska (suspended)
Anchorage Radiation Therapy Center — Anchorage, Alaska (suspended)
Alaska Breast Care and Surgery LLC — Anchorage, Alaska (suspended)
Alaska Oncology and Hematology LLC — Anchorage, Alaska (suspended)
Alaska Women's Cancer Care — Anchorage, Alaska (suspended)
Anchorage Oncology Centre — Anchorage, Alaska (suspended)
Katmai Oncology Group — Anchorage, Alaska (recruiting)
Providence Alaska Medical Center — Anchorage, Alaska (suspended)
Fairbanks Memorial Hospital — Fairbanks, Alaska (recruiting)
Cancer Center at Saint Joseph's — Phoenix, Arizona (recruiting)
Mercy Hospital Fort Smith — Fort Smith, Arkansas (suspended)
CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas (suspended)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Collection of Blood From Patients With Cancer

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.

NCT00034216 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phasePittsburgh, Pennsylvania

Not a traditional drug phase: Biopsy of the major carinal area for Lung Cancer

The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.

NCT00280202 · Official ClinicalTrials.gov record · University of Pittsburgh

FAQ about this NCT record

Is NCT04181060 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT04181060?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT04181060?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary